Q4 and Full Year 2025 Financial Results & Business Update Nasdaq: OABI March 4, 2026 1 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance for 2026, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our ...

Business Highlights - OmniAb had 95 active partners as of March 31, 2025[13, 15] - The company reported 378 active programs as of March 31, 2025, with over 98% having contracted future economics to OmniAb[17, 19] - OmniAb had 33 active clinical programs and approved products as of March 31, 2025[20, 22] - One new OmniAb-derived program, Genmab's GEN1078, entered a first-in-human clinical trial in Q1[24] - Post-discovery stage programs grew by 39% over the last 24 months[25] - OmniAb launched the xPloration Partner Access Program, expecting it to be accretive to earnings and cash flow in both the short- and long-term[11, 67] Financial Performance - Q1 2025 total revenue increased to $4.2 million compared to $3.8 million in Q1 2024, driven by license and milestone revenue[73, 75, 79] - License and milestone revenue was $2.0 million in Q1 2025, compared to $0.7 million in Q1 2024[79] - Service revenue decreased to $1.9 million in Q1 2025 from $2.8 million in Q1 2024[79] - Q1 2025 net loss was $18.2 million, compared to a net loss of $19.0 million in Q1 2024[79] - OmniAb is affirming revenue guidance of $20 million to $25 million for 2025[82] - Operating expense guidance revised to be in the range of $85 million to $90 million for 2025[82]